Dupilumab-Associated Blepharoconjunctivitis: Clinical and Morphological Aspects

被引:1
|
作者
Serino, Federica [1 ,2 ]
Dattilo, Valeria [1 ,2 ]
Cennamo, Michela [1 ,2 ]
Roszkowska, Anna Maria [3 ]
Gola, Massimo [4 ]
Magliulo, Manfredi [4 ]
Magnaterra, Elisabetta [4 ]
Mencucci, Rita [1 ,2 ]
机构
[1] Careggi Univ Hosp, Neuromuscular & Sense Organs Dept, Eye Clin, I-50139 Florence, Italy
[2] Univ Florence, Dept Neurosci Psychol Drug Res & Child Hlth, I-50019 Florence, Italy
[3] Univ Messina, Dept Biomed & Dent Sci & Morphofunct Imaging, I-98166 Messina, Italy
[4] Azienda USL Toscana Ctr, Allergol & Pediat Dermatol Unit, I-50122 Florence, Italy
关键词
Dupilumab; atopic dermatitis; meibomian glands; cornea; DRY EYE DISEASE; ATOPIC-DERMATITIS;
D O I
10.3390/biomedicines11123104
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Purpose: To describe the clinical and morphologic changes in the ocular surface microstructure of patients affected with moderate-to-severe Atopic Dermatitis (AD) before and during Dupilumab treatment. Methods: This is a monocentric observational study on thirty-three patients affected with AD before and during Dupilumab treatment. All patients underwent a slit-lamp examination: complete clinical assessment, Break Up Time test (BUT), Schirmer test, and corneal staining grading (Oxford scale) were performed. Meibomian Glands Dysfunction (MGD) evaluation (Meibography), Non-invasive Keratograph Break Up Time test (NIKBUT), Tear Meniscus Height (TMH), and ocular Redness Score (RS) have been investigated using an OCULUS Keratograph. In vivo images of the conjunctiva, cornea, and meibomian glands have been acquired by confocal microscopy. Results: Sixty-six eyes were included in our study: twenty-two eyes of 11 naive patients with indication for treatment but not in therapy yet (Group 1) and forty-four eyes of 22 patients treated with Dupilumab for at least 4 months (subcutaneous administration of 300 mg every 2 weeks) (Group 2). Either patients treated with Dupilumab or naive patients with moderate-to-severe forms of AD had a tear film instability (TBUT and NIKBUT reduced), whereas the quantity of the tear film was overall normal (Schirmer test and TMH), without statistically significant differences between the two groups. When Meibography was performed with the Keratograph, the difference between Group 1 and Group 2 was statistically significant in terms of Meiboscore (p = 0.0043 and p = 0.0242, respectively), as well as the difference in terms of mean RS. These results paired well with the confocal microscopy results in which we found a decrease in the goblet cell population in the conjunctival epithelium in the treated group (5.2 cells/mm), along with inflammatory cells that were more concentrated around the adenoid lumina of the meibomian glands. Conclusions: In recent years, the use of Dupilumab has been increasing, but mild-to-severe conjunctivitis is a common side effect. Our major results demonstrate a loss of meibomian glands at the Keratograph examination: we can assume a reduced meibum secretion and an evaporative dry eye with MGD. We suggest that the inflammation of the ocular surface may involve not only the cornea and the conjunctiva, but also the meibomian glands, and Dupilumab may play a role. However, the frequency of clear conjunctivitis is not as common as reported in the literature.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] MORE THAN MEETS THE EYE: A CASE OF DUPILUMAB-ASSOCIATED UVEITIS
    Lamothe, Pedro A.
    Runnstrom, Martin C.
    Smirnova, Natalia
    Lee, Frances E.
    CHEST, 2022, 162 (04) : 17A - 17A
  • [42] A Clinician’s Guide to the Recognition and Management of Dupilumab-Associated Conjunctivitis
    Gaurav Agnihotri
    Katherine Shi
    Peter A. Lio
    Drugs in R&D, 2019, 19 : 311 - 318
  • [43] A Clinician's Guide to the Recognition and Management of Dupilumab-Associated Conjunctivitis
    Agnihotri, Gaurav
    Shi, Katherine
    Lio, Peter A.
    DRUGS IN R&D, 2019, 19 (04) : 311 - 318
  • [44] Dupilumab-associated psoriasis and psoriasiform dermatitis in patients with atopic dermatitis
    Casale, Fiore
    Nguyen, Cristina
    Dobry, Allison
    Smith, Janellen
    Mesinkovska, Natasha Atanaskova
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2022, 63 (03) : 394 - 397
  • [45] Exploring patient background and biomarkers associated with the development of dupilumab-associated conjunctivitis and blepharitis
    Kido-Nakahara, Makiko
    Onozuka, Daisuke
    Izuhara, Kenji
    Saeki, Hidehisa
    Nunomura, Satoshi
    Takenaka, Motoi
    Matsumoto, Mai
    Kataoka, Yoko
    Fujimoto, Rai
    Kaneko, Sakae
    Morita, Eishin
    Tanaka, Akio
    Saito, Ryo
    Okano, Tatsuro
    Miyagaki, Tomomitsu
    Aoki, Natsuko
    Nakajima, Kimiko
    Ichiyama, Susumu
    Tonomura, Kyoko
    Nakagawa, Yukinobu
    Tamagawa-Mineoka, Risa
    Masuda, Koji
    Takeichi, Takuya
    Akiyama, Masashi
    Ishiuji, Yozo
    Katsuta, Michie
    Kinoshita, Yuki
    Tateishi, Chiharu
    Yamamoto, Aya
    Morita, Akimichi
    Matsuda-Hirose, Haruna
    Hatano, Yutaka
    Kawasaki, Hiroshi
    Fukushima-Nomura, Ayano
    Ohtsuki, Mamitaro
    Kamiya, Koji
    Kabata, Yudai
    Abe, Riichiro
    Mitsui, Hiroshi
    Kawamura, Tatsuyoshi
    Tsuji, Gaku
    Furue, Masutaka
    Katoh, Norito
    Nakahara, Takeshi
    ALLERGOLOGY INTERNATIONAL, 2024, 73 (02) : 332 - 334
  • [46] Dupilumab-Associated Mucin Deficiency (DAMD) (vol 9, 29, 2020)
    Barnett, Brad P.
    Afshari, Natalie A.
    TRANSLATIONAL VISION SCIENCE & TECHNOLOGY, 2020, 9 (08):
  • [47] Dermatology-ophthalmology collaborations are needed in dupilumab-associated ocular events
    Thompson, Alyssa M.
    Yu, Le
    Hsiao, Jennifer L.
    Shi, Vivian Y.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 84 (06) : E279 - E280
  • [48] Dupilumab-associated arthralgia in patients with aspirin-exacerbated respiratory disease
    Ozuna, Lorena Miss
    Ryan, Tessa
    Bensko, Jillian
    Laidlaw, Tanya C.
    Buchheit, Kathleen M.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2022, 128 (04) : 469 - 472
  • [49] Dupilumab-Associated Ocular Surface Disease: Clinical Characteristics, Treatment and Long-Term Follow Up
    Bohner, Austin
    Topham, Christina
    Haynes, Dylan
    Brazil, Molly
    Clements, John
    Simpson, Eric
    Chamberlain, Winston
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2020, 61 (07)
  • [50] Management of dupilumab-associated ocular surface diseases in atopic dermatitis patients
    Guex-Crosier, Yan
    Di-Lucca, Julie
    Hausermann, Peter
    Laffitte, Emmanuel
    Saulite, Ieva
    Schmid-Grendelmeier, Peter
    Schurch, Kaspar
    Thormann, Kathrin
    Simon, Dagmar
    SWISS MEDICAL WEEKLY, 2021, 151